|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
Given that osimertinib is the only approved third-generation EGFR-TKI against <i>EGFR</i> activating and resistant T790M mutated non-small cell lung cancer (NSCLC), additional mutant-selective inhibitors with a higher efficacy, especially for brain metastases, with favorable toxicity profile are still needed.
|
30670498 |
2019 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
We developed experimental brain metastasis models by intraventricular injection (intraventricular injection mouse model; IVM) of HER2-positive breast cancer (MDA-MB-361-luc-BR2/BR3) or T790M-EGFR-positive lung cancer (NCI-H1975-luc) cells.
|
29321587 |
2018 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
Brain metastasis-free survival was also longer in the T790M-positive group or osimertinib-treated group among patients who had no brain metastasis at the time of diagnosis.
|
29858020 |
2018 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure.
|
29721209 |
2018 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
Generally, the EGFR-T790M mutation was more common in NSCLC patients with brain metastasis and those who received TKI therapy for more than 6 months.
|
30337598 |
2018 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expert commentary: Osimertinib is the current treatment option for T790M mutation positive NSCLC after progression to first or second-generation EGFR TKIs, with activity also on brain metastasis.
|
30079781 |
2018 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
We experienced 2 NSCLC patients with the EGFR T790M mutation; a 67-year-old woman with symptomatic multiple brain metastases administered osimertinib as seventh-line chemotherapy, and a 76-year old man with an asymptomatic single brain metastasis administered osimertinib as fifth-line chemotherapy.
|
28178168 |
2017 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.
|
27486808 |
2016 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
We performed preclinical assessments of brain penetration and activity of osimertinib (AZD9291), an oral, potent, irreversible EGFR-TKI selective for EGFRm and T790M resistance mutations, and other EGFR-TKIs in various animal models of EGFR-mutant NSCLC brain metastases.
|
27435396 |
2016 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
The clinical features of EGFR T790M-mutant lung cancer were similar to those of sensitive EGFR-mutant lung cancer, except for the overrepresentation of never-smokers and brain metastasis.
|
25450875 |
2015 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
There is a possibility to detect the primary T790M mutation in brain metastases of NSCLC in EGFR-TKIs naïve patients.
|
24789720 |
2014 |
|
Metastatic malignant neoplasm to brain
|
|
0.100 |
GeneticVariation
|
BEFREE |
Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.
|
17085664 |
2006 |